Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
NCT03537599 · Sumithira Vasu · PHASE1/PHASE2 · terminated · last registry update 2025-05-21 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor acccrual” | Open Targets' class: insufficient enrollment | Registry record, Sumithira Vasu |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD38 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-19Results posted on the registry: Genmab, GEN3014 + Daratumumab (NCT04824794)
- 2026-05-19Also stopped (terminated): Genmab, GEN3014 + Daratumumab (NCT04824794)
- 2024-12-13Results posted on the registry: Syros Pharmaceuticals, Tamibarotene + Azacitidine (NCT02807558)
- 2024-10-24Results posted on the registry: Masonic Cancer Center, University of Minnesota, Daratumumab/rHuPH20 + FT538 (NCT04714372)
- 2024-09-03Also stopped (terminated): Pfizer, Maplirpacept (PF-07901801) + Azacitidine (NCT03530683)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision